TWiV 1048: Clinical update with Dr. Daniel Griffin
In his weekly clinical update, Dr. Griffin discusses a molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, inhaled fluticasone furoate for outpatient treatment of COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, early antibody treatment, inflammation, and risk of post-COVID conditions, autonomic dysregulation in long-term patients suffering from post-COVID-19 syndrome assessed by heart rate variability, and multiorgan MRI findings after hospitalization with COVID-19 in the UK.
Subscribe (free): Apple Podcasts,\xa0Google Podcasts,\xa0RSS,\xa0email
Become a\xa0patron\xa0of\xa0TWiV!
Links for this episode- Molnupiravir-associated mutational signature in global SARS-CoV-2 genomes (Nature)
- Inhaled fluticasone furoate for outpatient treatment of\xa0COVID-19\xa0(NEJM)
- Optimal duration\xa0of systemic corticosteroids in COVID-19 treatment (OFID)
- Distinguishing features of Long COVID identified through\xa0immune profiling\xa0(Nature)
- Early antibody treatment, inflammation, and risk of post-COVID conditions (mBIO)
- Autonomic dysregulation in long-term patients suffering from\xa0post COVID-19 syndrome\xa0(SR)
- Multiorgan MRI findings\xa0after hospitalization with COVID-19 in the UK (The Lancet)
- Contribute to our\xa0Floating Doctors fundraiser at PWB
- Letters read\xa0on TWiV 1048
- Dr. Griffin\u2019s COVID treatment summary (pdf)
- Timestamps by\xa0Jolene. Thanks!
Intro music is by\xa0Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv